Results 191 to 200 of about 82,694 (258)

Homoisoflavonoids—From Natural Specificity and Biosynthesis to Precision Health‐Promoting Mechanisms

Food Frontiers, Volume 7, Issue 3, May 2026.
Homoisoflavonoids are rare flavonoids with a unique bi‐aromatic oxygen‐heterocyclic structure. This review synthesizes their structure–activity relationships in anti‐inflammatory, hypoglycemic, and anticancer contexts. By highlighting their specific natural distribution and outlining biosynthetic pathways, it provides a conceptual framework and ...
Jing Zhang, Han Chen, Jinping Si, Zhigang Han, Xinfeng Zhang   +4 more
wiley   +1 more source

Trials evaluating nicorandil renoprotection against contrast-induced nephropathy after coronary angiography or percutaneous coronary intervention: a systematic review and meta-analysis. [PDF]

Egypt Heart J
Ferreira NL, Aguiar DR, Nair SG, Shehab MA, Adelowo AB, Damirchi MR, Jones D, Rathod K, Khan Z.   +8 more
europepmc   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

Association of triglyceride-glucose index and high-sensitivity C-reactive protein with contrast-induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome: a retrospective cohort study. [PDF]

Front Cardiovasc Med
Tian G, Qian C, Liu Z, Xu Y, Yang L, He L.   +5 more
europepmc   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

RETRACTION: Berberine Alleviates Contrast-Induced Nephropathy by Activating Akt/Foxo3a/Nrf2 Signalling Pathway. [PDF]

J Cell Mol Med
europepmc   +1 more source

The Incidence of Contrast-Induced Nephropathy Among Low-Risk Cancer Patients with Preserved Renal Function on Active Treatment Undergoing Contrast-Enhanced Computed Tomography: A Single-Site Experience. [PDF]

Healthcare (Basel)
Subahi A, Alhazmi N, Lardi M, Alkathiri F, Bokhari L, Alqahtani S, Abourokba N, Alshamrani K.   +7 more
europepmc   +1 more source

Identification of a Novel De Novo Heterozygous SEC61A1 Variant in a Patient With Severe Congenital Neutropenia

Molecular Genetics &Genomic Medicine, Volume 14, Issue 5, May 2026.
Severe congenital neutropenia can be caused by rare SEC61A1 variants. We report a child with SCN showing granulocytic maturation arrest and abnormal immunophenotype, carrying a novel de novo SEC61A1 p.Trp379Arg variant, expanding the phenotypic and genetic spectrum of SEC61A1‐associated SCN.
Zixuan Wang, Hui Jing, Yuhan Chen, Ling Zhong, Jiyun Yang   +4 more
wiley   +1 more source

Diagnostic Value of Sirtuin-1 in Predicting Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. [PDF]

J Clin Med
Ardic M, Gul CB.
europepmc   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source